Biotech Looks Anew at Old Ideas On Using the Body's Own Defenses
Article Abstract:
Biotechnology and pharmaceutical companies like Coley Pharmaceutical Group are investing millions of dollars developing drugs that use toll-like receptors, a class of human proteins. These new drugs, which attempt to stimulate the immune system, may be used to treat cancer, hepatitis C and even asthma.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
France, Financial management, Science & research, Securities issued, listed, Cellular Protein, In-Vitro Diagnostic Substance Manufacturing, Research, Company investment, Investments, Securities, Pfizer Inc., Cellular proteins, Immunosuppressive agents, PFE, Company securities, SNY, Sanofi-Aventis S.A., Immunopharmacology, Coley Pharmaceutical Group Inc.
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
In Clinical Trials, Drug Protects Brain From Stroke Damage
Article Abstract:
Share of biotechnology company Renovis Inc. and pharmaceutical company AstraZeneca went up yesterday with news of partially successful clinical trials of Cerovive, a new drug to reduce disability from stroke.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
United Kingdom, Biotechnology industry, Biotechnology industries, Drug therapy, Stroke (Disease), Stroke, AstraZeneca PLC, AZN, Neuropharmacology, Renovis Inc., Cerovive (Medication)
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Product development, Pharmaceutical industry
Similar abstracts:
- Abstracts: Mitsubishi Looks for Buyers and Its Niche. Fitting In the Odd Piece. Chrysler Aloof, So Far, From Latest Incentive War
- Abstracts: Since Hurricane Katrina Rolled In, the Cash Has Rolled Out. Google Is One For the Books, Leaving Some With Regrets
- Abstracts: Fall Season Looks Solid for Retailers, But Holidays Could Be Another Story. Ballet Flats? Walking Shoes? Nah. It's Round Toes and High Heels
- Abstracts: Halliburton Uses Loophole to Reduce Payouts at an Upstate New York Unit
- Abstracts: Oil Nears $50 As Gulf Storms Curtail Output. Behind the Bouncing Ball of Oil Prices
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.